CPX-351 (citarabina lipossomal e daunorrubicina) versus terapia com venetoclax mais agente hipometilante em leucemia mieloide aguda recém-diagnosticada: uma comparação retrospectiva envolvendo 600 pacientes da Mayo Clinic | Blood Cancer Journal – Nature
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving…
Conteudo completo do artigo
The comparative value of liposomal cytarabine/daunorubicin (CPX-351) versus venetoclax plus a hypomethylating agent (Ven-HMA) in the frontline treatment of older adults with primary (de novo) or secondary acute myeloid leukemia (AML) remains uncertain. In the current study, we retrospectively examined outcomes of 600 patients with newly diagnosed AML treated with CPX-351 (N = 112) or Ven-HMA (N = 488). AML subtypes included de novo (N = 277,46%), post-myelodysplastic syndrome (post-MDS, N = 114,19%), post-myeloproliferative neoplasm (post-MPN, N = 70,12%), post-MDS/MPN (N = 36,6%), and t-AML (N = 103,17%). Patients receiving CPX-351 were younger (median 65 vs. 73 years; p
Produtos relacionados com este artigo
Estes produtos foram associados automaticamente a partir do titulo, resumo e conteudo do artigo.
Perguntas frequentes
Which products are related to this article?
The system matched these relevant products from the article content: Lucius Venetoclax – Compre online VECLADX Venetoclax 100mg.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.